ArticleVeterinary clinical pathology2025
Analytical Validation of an Automated Point-of-Care Immunoassay for the Measurement of Feline Pancreatic Lipase Immunoreactivity Concentration (Vcheck fPL 2.0).
Article in Veterinary clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPancreatic lipase assays are commonly utilized in the diagnostic approach to suspected pancreatitis in cats. The Vcheck fPL 2.0 assay is commercially available; however, analytical validation has yet to be reported in the peer-reviewed literature.
objectiveTo evaluate the analytic validity of a fluorescent immunoassay for the point-of-care quantification of feline pancreatic lipase immunoreactivity (Vcheck fPL 2.0 assay).
methodsLinearity was assessed via dilutional parallelism. Intra- and interassay variability was assessed by calculating coefficients of variation (%CV) across replicates on the same day and across multiple days, respectively. Bilirubin, hemoglobin, and intralipid (intralipid 30% IV emulsion, VWR, Radnor, PA, USA) were utilized to evaluate the potential effects of interfering substances on the assay.
resultsLinearity was sub-optimal, with 12/15 diluted runs having an O/E ratio outside of the 80-120% target range. The mean %CV was 10.2% for intra-assay variability and 16.3% for interassay variability. Interfering substances had no significant effect on the results of the Vcheck fPL 2.0 assay (P = 0.888).
conclusionsThe Vcheck fPL 2.0 appears to have poor linearity and suboptimal precision, limiting the accurate interpretation of results. Additional assay optimization should be considered prior to routine clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.